Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-02-13 Director's Dealing
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Further CEO Share Purchase
Director's Dealing Classification · 100% confidence The document is a notification of a share purchase by the CEO of Renalytix plc, detailing the transaction of shares bought, the price, volume, and date. It includes information about the person discharging managerial responsibilities (the CEO) and the nature of the transaction (purchase of ordinary shares). This type of document is a report of personal share transactions by a company director, which fits the definition of Director's Dealing (DIRS). The document is not a financial report, earnings release, or any other type of report but a regulatory announcement of insider share transactions.
2026-02-13 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a notification of a share purchase transaction by a director-level individual (Joel Jung, interim CFO) of Renalytix plc. It details the purchase of American Depositary Shares, the price, volume, and date of the transaction. The document is a regulatory announcement about insider dealings, specifically personal share transactions by a company director. There is no financial report, earnings data, or management discussion. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives.
2026-02-13 English
Director/PDMR Share Purchase
Director's Dealing Classification · 95% confidence The document is a notification of a share purchase transaction by a director-level individual (Joel Jung, interim CFO) of Renalytix plc. It details the purchase of 2,000 American Depositary Shares, including price, volume, and date of transaction. The document is titled 'Director / PDMR Share Purchase' and includes specific transaction details, but does not contain financial statements, earnings data, or report content. It is a regulatory announcement about insider trading activity, which fits the definition of Director's Dealing (DIRS). The document length is 6814 characters, sufficient for a detailed transaction report. There is no indication that this is a full financial report or an announcement of a report publication. Therefore, the correct classification is DIRS with high confidence.
2026-02-12 English
CEO Share Purchase
Director's Dealing Classification · 100% confidence The document is a formal notification of a share purchase by a person discharging managerial responsibilities (PDMR), specifically the CEO of Renalytix plc. It includes the required regulatory disclosure table for transactions by directors/executives, detailing the nature of the transaction, price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-02-12 English
H1 Trading update
Interim / Quarterly Report Classification · 95% confidence The document is titled 'H1 Trading update' and provides unaudited revenue figures for the six months ended 31 December 2025 (H1 FY26). It discusses current trading performance, new integrations, collaborations, operational improvements, and future expectations. The document explicitly states it is a trading update for the half-year period and mentions that unaudited interim results will be announced later. It does not contain full financial statements or detailed financial analysis but rather a summary of trading performance and operational highlights. This fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains substantive financial data and analysis. The document is not merely an announcement of a report but provides actual financial and operational information. Therefore, the correct classification is IR with high confidence.
2026-02-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. This is a regulatory requirement for shareholders to disclose when their voting rights in a company cross specific thresholds. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2026-01-21 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.